A non-selective peripheral anticholinergic agent (nsPAChA) selected from the group consisting of: * quaternary ammonium-based nsPAChA or sulfonium-based nsPAChA represented by formula (II) ** Formula ** in which: - R is a radical selected from the group consisting of those of formulas (a) - (e) ** Formula ** being A methyl and A3 being a (C1-C4) alkyl or 2-fluoroethyl group, or forming A and A 'a chain of 1 , 4-butylene or 1,5-pentylene, where L is hydrogen or methoxy, where Alq and Alq '(C1-C4) alkyl are each, and Y is a bivalent radical selected from the group consisting of 1,2-ethylene, 1, 3-propylene, 1,4-butylene and 2-oxa-1,3-propylene； the corresponding counterion being a pharmaceutically acceptable anion, - nym, independently, are zero or 1, - X is an alkylene group (C2-C3), - R1 and R2 are each phenyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 2- thienyl and, when R is a radical (a), each also represents (C1-C4) alkyl, - R3 is H or OH or, only when R is a radical (a), also a COOAlq group, where Alq is a group (C1-C4) alkyl, * solifenacin and its pharmaceutically acceptable salts, * propiverine and its pharmaceutically acceptable salts, * oxyphenylcycline and its pharmaceutically acceptable salts, and * tolterodine and its pharmaceutically acceptable salts； in combination with an acetylcholinesterase inhibitor (AChEI) with a dosage of 1.5 to 4 times greater than the maximum tolerated dose of said AChEI for use in the treatment of Alzheimer's dementia in a patient； wherein said AChEI is selected from the group consisting of tacrine, donepezil, rivastigmine, galantamine and pharmaceutically acceptable salts thereof.Un agente anticolinérgico periférico no selectivo (nsPAChA) seleccionado del grupo constituido por: * los nsPAChA a base de amonio cuaternario o los nsPAChA a base de sulfonio representados por la fórmula (II) **Fórmula** en la que: - R es un radical seleccionado del grupo constituido por los de fórmulas (a)-(e) **Fórmula** siendo A metilo y siendo A
